Gossamer Bio, Inc.
GOSS
$2.46
-$0.07-2.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.24M | 124.59M | 114.70M | 105.32M | 95.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.24M | 124.59M | 114.70M | 105.32M | 95.84M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 40.24M | 124.59M | 114.70M | 105.32M | 95.84M |
| SG&A Expenses | 35.23M | 35.22M | 36.13M | 35.80M | 36.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 185.86M | 179.36M | 174.62M | 168.14M | 165.23M |
| Operating Income | -145.62M | -54.77M | -59.92M | -62.82M | -69.39M |
| Income Before Tax | -142.29M | -50.35M | -55.64M | -68.34M | -76.42M |
| Income Tax Expenses | -3.54M | 893.00K | 893.00K | 3.30M | 4.44M |
| Earnings from Continuing Operations | -138.74 | -51.24 | -56.53 | -71.65 | -80.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -138.74M | -51.24M | -56.53M | -71.65M | -80.85M |
| EBIT | -145.62M | -54.77M | -59.92M | -62.82M | -69.39M |
| EBITDA | -145.29M | -54.19M | -59.09M | -61.80M | -68.20M |
| EPS Basic | -0.76 | -0.37 | -0.40 | -0.32 | -0.39 |
| Normalized Basic EPS | -0.56 | -0.31 | -0.32 | -0.19 | -0.23 |
| EPS Diluted | -0.76 | -0.37 | -0.40 | -0.32 | -0.39 |
| Normalized Diluted EPS | -0.56 | -0.32 | -0.33 | -0.20 | -0.24 |
| Average Basic Shares Outstanding | 907.04M | 905.99M | 904.91M | 903.71M | 870.25M |
| Average Diluted Shares Outstanding | 907.04M | 918.31M | 917.23M | 916.03M | 882.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |